ZNTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zentalis Pharmaceuticals Inc (ZNTL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive momentum, strong analyst support, and promising drug development catalysts, despite weak financials. The pre-market price increase and technical indicators suggest potential for further growth.
The MACD is positive at 0.278 and contracting, indicating bullish momentum. RSI is neutral at 61.138, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 6.286 and R2: 7.362, while support levels are at S1: 2.802 and S2: 1.726. The pre-market price is $5.12, up 1.99%, showing positive sentiment.
Guggenheim raised the price target from $6 to $10, citing increased confidence in the drug's potential success.
Positive news on the ovarian cancer treatment with a higher response rate at 400 mg dose.
Shares surged over 40% recently, reflecting strong market optimism.
Financial performance is weak, with revenue and gross margin dropping to 0 in Q4
Net income and EPS have significantly declined YoY.
No recent insider or hedge fund trading trends to indicate strong institutional support.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income dropped to -$35.22M (-25.82% YoY), and EPS dropped to -0.49 (-26.87% YoY). Gross margin also dropped to 0 (-100% YoY), indicating poor financial health.
Guggenheim maintains a Buy rating and raised the price target from $6 to $10, citing increased confidence in the success of Zentalis's ovarian cancer treatment.
